{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-25-000657","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.938541+00:00","generated_at":"2026-05-19T04:23:00.487634+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients","bullets":["Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.","Sleep disturbance improved 71% at week 2 (p=0.012) and 78% at week 6 (p=0.02) on NPI-12 sleep subdomain.","Phase 1 (n=13): no SAEs; agitation reduced significantly across all doses (p<0.05 each) on NPI agitation domain.","Genotype-dependent PK: intermediate CYP2C9 metabolizers had longer IGC-AD1 half-life, potential for personalized dosing.","Phase 2 CALMA trial targeting full enrollment of 146 participants for agitation in Alzheimer's dementia."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-25-000657","json":"https://secwatch.observer/filing/0001185185-25-000657.json","markdown":"https://secwatch.observer/filing/0001185185-25-000657.md","text":"https://secwatch.observer/filing/0001185185-25-000657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518525000657/0001185185-25-000657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518525000657/igc8k061425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:23:00.487634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}